Roche also reported that no new safety concerns were identified, reinforcing Elevidys's consistent and manageable safety profile observed to date. This article was generated with the support of AI ...

Roche announced positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys (delandistrogene moxeparvovec), the first approved gene ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...

Roche acquired commercial rights to Elevidys outside the US under a 2019 deal with Sarepta, and some analysts have predicted that sales of the treatment could eventually reach $2 billion to $4 ...

Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene moxeparvovec) in children with the rare muscle-wasting disorder Duchenne ...

Roche's Q4 results and innovative advancements make it a strong pick. Its late-stage pipeline supports our belief that there ...

The company’s management has demonstrated exceptional proficiency in launching Elevidys, achieving over 110% quarter-over-quarter growth and surpassing market expectations by approximately 17% ...

Royalty revenue from the sales of ELEVIDYS by Roche for the quarter totaled $4.9 million – Achieved GAAP and non-GAAP net income of $159.0 million and $206.0 million for the fourth quarter of ...

of contract manufacturing and other revenues associated with commercial ELEVIDYS supply delivered to Roche and royalty revenue received from Roche, as compared to $9.2 million of contract ...